drugset / Trial / NCT06237920
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Phase 2
Active not recruiting
90 enrolled
The Netherlands Cancer Institute
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment
Timeline
- Start
- 2024-02-19
- Primary completion
- 2026-12-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relatlimab | Monoclonal antibody | — | Intravenous |
| Background | Nivolumab | Monoclonal antibody | — | Intravenous |